Experience with the use of intravitreal bevacizumab in cases with type I retinopathy of prematurity in a Latin American country

C. Zuluaga-Botero; N. González; G. Escobar; E. Cantor; A. Martínez-Blanco

doi:10.1016/j.oftal.2024.03.012

Experience with the use of intravitreal bevacizumab in cases with type I retinopathy of prematurity in a Latin American country

Título traducido de la contribución: Experiencia con el uso de bevacizumab intravítreo en el manejo de la retinopatía del prematuro tipo I en un país latinoamericano

C. Zuluaga-Botero
, N. González
, G. Escobar
, E. Cantor
, A. Martínez-Blanco

Departamento de Epidemiología Clínica y Bioestadística

Universidad del Valle
Clínica Imbanaco - Quiron Salud
Instituto para Niños Ciegos y Sordos del Valle del Cauca
Pontificia Universidad Javeriana

Producción: Contribución a una revista › Artículo › revisión exhaustiva

Resumen

In retinopathy of prematurity (ROP) type I, the use of intravitreal bevacizumab (IVB), which is an inhibitor of endothelial growth factor (VEGF), has become popular despite not being a therapy approved by regulatory agencies. However, IVB has shown positive effects in halting disease progression at lower costs compared to other anti-VEGF therapies (ranibizumab or aflibercept). In this report, we present the experience during the treatment with IVB of 102 Colombian children with ROP type I, with a success rate of 98% (100). Complications occurred in 3.9% (4). Finally, we conclude that a single dose of IVB is an effective therapy for the management of ROP type I, with a lower risk of complications and retreatment.

Título traducido de la contribución	Experiencia con el uso de bevacizumab intravítreo en el manejo de la retinopatía del prematuro tipo I en un país latinoamericano
Idioma original	Inglés
Páginas (desde-hasta)	400-403
Número de páginas	4
Publicación	Archivos de la Sociedad Espanola de Oftalmologia
Volumen	99
N.º	9
DOI	https://doi.org/10.1016/j.oftal.2024.03.012
Estado	Publicada - sept 2024

Acceder al documento

10.1016/j.oftal.2024.03.012

Otros archivos y enlaces

Enlace a la publicación en Scopus

Citar esto

@article{f6469e2319494e39a45107313b15afdc,

title = "Experience with the use of intravitreal bevacizumab in cases with type I retinopathy of prematurity in a Latin American country",

abstract = "In retinopathy of prematurity (ROP) type I, the use of intravitreal bevacizumab (IVB), which is an inhibitor of endothelial growth factor (VEGF), has become popular despite not being a therapy approved by regulatory agencies. However, IVB has shown positive effects in halting disease progression at lower costs compared to other anti-VEGF therapies (ranibizumab or aflibercept). In this report, we present the experience during the treatment with IVB of 102 Colombian children with ROP type I, with a success rate of 98\% (100). Complications occurred in 3.9\% (4). Finally, we conclude that a single dose of IVB is an effective therapy for the management of ROP type I, with a lower risk of complications and retreatment.",

keywords = "Aflibercept, Bevacizumab, Endothelial growth factor inhibitor, Retinopathy of prematurity",

author = "C. Zuluaga-Botero and N. Gonz{\'a}lez and G. Escobar and E. Cantor and A. Mart{\'i}nez-Blanco",

note = "Publisher Copyright: {\textcopyright} 2024 Sociedad Espa{\~n}ola de Oftalmolog{\'i}a",

year = "2024",

month = sep,

doi = "10.1016/j.oftal.2024.03.012",

language = "English",

volume = "99",

pages = "400--403",

journal = "Archivos de la Sociedad Espanola de Oftalmologia",

issn = "0365-6691",

publisher = "Elsevier Ltd.",

number = "9",

}

TY - JOUR

T1 - Experience with the use of intravitreal bevacizumab in cases with type I retinopathy of prematurity in a Latin American country

AU - Zuluaga-Botero, C.

AU - González, N.

AU - Escobar, G.

AU - Cantor, E.

AU - Martínez-Blanco, A.

PY - 2024/9

Y1 - 2024/9

N2 - In retinopathy of prematurity (ROP) type I, the use of intravitreal bevacizumab (IVB), which is an inhibitor of endothelial growth factor (VEGF), has become popular despite not being a therapy approved by regulatory agencies. However, IVB has shown positive effects in halting disease progression at lower costs compared to other anti-VEGF therapies (ranibizumab or aflibercept). In this report, we present the experience during the treatment with IVB of 102 Colombian children with ROP type I, with a success rate of 98% (100). Complications occurred in 3.9% (4). Finally, we conclude that a single dose of IVB is an effective therapy for the management of ROP type I, with a lower risk of complications and retreatment.

AB - In retinopathy of prematurity (ROP) type I, the use of intravitreal bevacizumab (IVB), which is an inhibitor of endothelial growth factor (VEGF), has become popular despite not being a therapy approved by regulatory agencies. However, IVB has shown positive effects in halting disease progression at lower costs compared to other anti-VEGF therapies (ranibizumab or aflibercept). In this report, we present the experience during the treatment with IVB of 102 Colombian children with ROP type I, with a success rate of 98% (100). Complications occurred in 3.9% (4). Finally, we conclude that a single dose of IVB is an effective therapy for the management of ROP type I, with a lower risk of complications and retreatment.

KW - Aflibercept

KW - Bevacizumab

KW - Endothelial growth factor inhibitor

KW - Retinopathy of prematurity

UR - https://www.scopus.com/pages/publications/85190744532

U2 - 10.1016/j.oftal.2024.03.012

DO - 10.1016/j.oftal.2024.03.012

M3 - Article

AN - SCOPUS:85190744532

SN - 0365-6691

VL - 99

SP - 400

EP - 403

JO - Archivos de la Sociedad Espanola de Oftalmologia

JF - Archivos de la Sociedad Espanola de Oftalmologia

IS - 9

ER -

Experience with the use of intravitreal bevacizumab in cases with type I retinopathy of prematurity in a Latin American country

Resumen

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto